Jefferies Financial Group Weighs in on AstraZeneca plc’s Q2 2020 Earnings (NYSE:AZN)
AstraZeneca plc (NYSE:AZN) – Research analysts at Jefferies Financial Group lifted their Q2 2020 earnings estimates for shares of AstraZeneca in a research report issued to clients and investors on Thursday, July 9th. Jefferies Financial Group analyst P. Welford now expects that the company will earn $0.41 per share for the quarter, up from their previous forecast of $0.40. Jefferies Financial Group also issued estimates for AstraZeneca’s FY2021 earnings at $2.45 EPS and FY2022 earnings at $3.11 EPS.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.06. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The business had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $5.95 billion. During the same period last year, the business posted $0.89 EPS. The business’s revenue was up 16.3% compared to the same quarter last year.
Shares of AZN stock opened at $53.24 on Monday. AstraZeneca has a 1-year low of $36.15 and a 1-year high of $57.44. The stock’s fifty day moving average price is $53.45 and its 200 day moving average price is $49.67. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.75 and a quick ratio of 0.57. The company has a market cap of $141.09 billion, a price-to-earnings ratio of 90.24, a price-to-earnings-growth ratio of 1.60 and a beta of 0.55.
Institutional investors have recently bought and sold shares of the business. Patriot Financial Group Insurance Agency LLC grew its stake in AstraZeneca by 223.8% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 557 shares of the company’s stock valued at $25,000 after purchasing an additional 385 shares during the last quarter. OmniStar Financial Group Inc. acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $26,000. Verus Capital Partners LLC acquired a new position in shares of AstraZeneca in the 4th quarter valued at about $27,000. Golden State Wealth Management LLC acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $31,000. Finally, Gemmer Asset Management LLC lifted its holdings in shares of AstraZeneca by 272.3% in the 1st quarter. Gemmer Asset Management LLC now owns 752 shares of the company’s stock valued at $34,000 after buying an additional 550 shares during the period. Institutional investors and hedge funds own 16.84% of the company’s stock.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: How does a reverse stock split work?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.